Abpro Holdings (ABPO) Common Equity (2021 - 2026)
Abpro Holdings' (ABPO) quarterly Common Equity came in at -$2.3 million in Q1 2026, up 87.36% YoY from -$1.2 million in Q1 2025, and up 72.81% on a QoQ basis from -$8.3 million in Q4 2025.
Abpro Holdings (ABPO) Common Equity (2021 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 6 years of Common Equity data on file, last reported at -$2.3 million in Q1 2026.
- Quarterly Common Equity rose 87.36% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 million (up 87.36% YoY) and the FY2025 annual result came in at -$8.3 million, up 44.59% from the prior year.
- Common Equity grew to -$2.3 million in Q1 2026, from -$8.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$2.3 million in Q1 2026 to a low of -$90.8 million in Q3 2024.
- A 5-year average of -$34.3 million and a median of -$15.1 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 340661.04% — and 2026, when it jumped 87.36%.
- Tracing ABPO's Common Equity over 5 years: stood at -$79.0 million in 2022, then slipped by 11.89% to -$88.4 million in 2023, then soared by 83.1% to -$14.9 million in 2024, then jumped by 44.59% to -$8.3 million in 2025, then soared by 72.81% to -$2.3 million in 2026.
- The last three Common Equity figures came in at -$2.3 million (Q1 2026), -$8.3 million (Q4 2025), and -$15.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | -3.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.25 Mn |
| Dec 31, 2025 | -8.28 Mn |
| Sep 30, 2025 | -15.60 Mn |
| Jun 30, 2025 | -16.95 Mn |
| Mar 31, 2025 | -17.81 Mn |
| Dec 31, 2024 | -14.95 Mn |
| Sep 30, 2024 | -90.80 Mn |
| Jun 30, 2024 | -89.12 Mn |
| Mar 31, 2024 | -87.24 Mn |
| Dec 31, 2023 | -88.44 Mn |
| Sep 30, 2023 | -15.06 Mn |
| Jun 30, 2023 | -14.81 Mn |
| Mar 31, 2023 | -11.66 Mn |
| Dec 31, 2022 | -79.03 Mn |
| Sep 30, 2022 | -10.64 Mn |
| Jun 30, 2022 | -10.19 Mn |
| Mar 31, 2022 | -9.99 Mn |
| Dec 31, 2021 | 23,207.00 |